Cargando…

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients

Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients. Methods: The plasma prote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bridel, Claire, Eijlers, Anand J. C., van Wieringen, Wessel N., Koel-Simmelink, Marleen, Leurs, Cyra E., Schoonheim, Menno M., Killestein, Joep, Teunissen, Charlotte E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220078/ https://www.ncbi.nlm.nih.gov/pubmed/30429773 http://dx.doi.org/10.3389/fnmol.2018.00371

Ejemplares similares

Plasma proteome in multiple sclerosis disease progression
por: Malekzadeh, Arjan, et al.
Publicado: (2019)

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis
por: Loonstra, Floor C., et al.
Publicado: (2022)

Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers
por: Coric, Danko, et al.
Publicado: (2017)

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
por: Chatterjee, Madhurima, et al.
Publicado: (2018)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
por: Bridel, Claire, et al.
Publicado: (2017)

Sensorimotor network dynamics predict decline in upper and lower limb function in people with multiple sclerosis
por: Strik, Myrte, et al.
Publicado: (2022)

Dynamic functional connectivity as a neural correlate of fatigue in multiple sclerosis
por: Tijhuis, Floris B., et al.
Publicado: (2021)

Gray matter networks and cognitive impairment in multiple sclerosis
por: Rimkus, Carolina M, et al.
Publicado: (2018)

Serum Contactin-1 in CIDP: A Cross-Sectional Study
por: Wieske, Luuk, et al.
Publicado: (2021)

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment
por: Leurs, Cyra E, et al.
Publicado: (2017)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis
por: Sestito, Claudia, et al.
Publicado: (2021)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Association of Arachidonic Acid–Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis
por: Broos, Jelle Y., et al.
Publicado: (2023)

Blood platelet RNA enables the detection of multiple sclerosis
por: Sol, Nik, et al.
Publicado: (2020)

Production of Plasmatic Cell Juices—Experiments in Immunization and Clinical Treatment with the Plasmatic Cell Juices of Bacteria
Publicado: (1898)

Adipokines in multiple sclerosis patients are related to clinical and radiological measures
por: Loonstra, Floor C., et al.
Publicado: (2022)

The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis
por: Schoonheim, Menno M, et al.
Publicado: (2021)

Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE)
por: Camu, William, et al.
Publicado: (2019)

Relapsing–remitting clinical course expands the phenotype of Aicardi–Goutières syndrome
por: Lambe, Jeffrey, et al.
Publicado: (2020)

Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis
por: Chalkou, Konstantina, et al.
Publicado: (2021)

Predicting clinical progression in multiple sclerosis after 6 and 12 years
por: Dekker, I., et al.
Publicado: (2019)

The sequence of structural, functional and cognitive changes in multiple sclerosis
por: Dekker, Iris, et al.
Publicado: (2020)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran
por: Ouspid, Elham, et al.
Publicado: (2018)

In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
por: Sips, Fianne L. P., et al.
Publicado: (2022)

Relapsing/remitting type 1 diabetes
por: van Megen, Kayleigh M., et al.
Publicado: (2017)

Relapsing–remitting painful ophthalmoplegia due to orbital myositis
por: Guaschino, E., et al.
Publicado: (2005)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability
por: Migliore, S., et al.
Publicado: (2017)

Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome
por: PAVELEK, ZBYŠEK, et al.
Publicado: (2016)

Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy
por: Almouzain, Lubna, et al.
Publicado: (2021)

A Case of Relapsing-Remitting Tumefactive Demyelination
por: Wadhwa, Ankur, et al.
Publicado: (2019)

Relapsing and remitting viral diseases of the nervous system
por: Johnson, Richard T.
Publicado: (1984)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_352l2kq6n104e28iooa36c32ou